Fusion Antibodies PLC (FAB) - Total Liabilities

Latest as of September 2025: GBX1.09 Million GBX ≈ $132.13 USD

Based on the latest financial reports, Fusion Antibodies PLC (FAB) has total liabilities worth GBX1.09 Million GBX (≈ $132.13 USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Fusion Antibodies PLC (FAB) equity growth momentum to track the company's year-over-year net asset growth rate.

Fusion Antibodies PLC - Total Liabilities Trend (2006–2025)

This chart illustrates how Fusion Antibodies PLC's total liabilities have evolved over time, based on quarterly financial data. See Fusion Antibodies PLC (FAB) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Fusion Antibodies PLC Competitors by Total Liabilities

The table below lists competitors of Fusion Antibodies PLC ranked by their total liabilities.

Company	Country	Total Liabilities
Prospex Energy PLC LSE:PXEN	UK	GBX992.70K
Fulcrum Metals PLC LSE:FMET	UK	GBX751.81K
Vergnet PA:ALVER	France	€41.97 Million
Lexington Gold Ltd LSE:LEX	UK	GBX593.00K
Tasty Plc LSE:TAST	UK	GBX36.13 Million
genedrive plc LSE:GDR	UK	GBX1.38 Million
CROSS RIVER VENTURES CORP F:C6R	Germany	€1.11 Million

Liability Composition Analysis (2006–2025)

This chart breaks down Fusion Antibodies PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FAB company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.80	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.50	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.60	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Fusion Antibodies PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Fusion Antibodies PLC (2006–2025)

The table below shows the annual total liabilities of Fusion Antibodies PLC from 2006 to 2025.

Year	Total Liabilities	Change
2025-03-31	GBX654.00K ≈ $79.57	+4.31%
2024-03-31	GBX627.00K ≈ $76.29	-33.23%
2023-03-31	GBX939.00K ≈ $114.25	-23.72%
2022-03-31	GBX1.23 Million ≈ $149.78	+13.67%
2021-03-31	GBX1.08 Million ≈ $131.77	-11.81%
2020-03-31	GBX1.23 Million ≈ $149.41	+38.21%
2019-03-31	GBX888.53K ≈ $108.11	+40.24%
2018-03-31	GBX633.59K ≈ $77.09	+40.73%
2017-03-31	GBX450.22K ≈ $54.78	+9.43%
2016-03-31	GBX411.43K ≈ $50.06	+104.01%
2015-03-31	GBX201.67K ≈ $24.54	-32.23%
2014-03-31	GBX297.57K ≈ $36.21	+17.35%
2013-03-31	GBX253.56K ≈ $30.85	-42.76%
2012-03-31	GBX443.00K ≈ $53.90	+15.97%
2011-03-31	GBX382.00K ≈ $46.48	+25.25%
2010-03-31	GBX305.00K ≈ $37.11	-51.82%
2009-03-31	GBX633.00K ≈ $77.02	+37.01%
2008-03-31	GBX462.00K ≈ $56.21	+3.36%
2007-03-31	GBX447.00K ≈ $54.39	+54.14%
2006-03-31	GBX290.00K ≈ $35.28	--

About Fusion Antibodies PLC

LSE:FAB UK Biotechnology

Market Cap

$145.20K

GBX1.19 Billion GBX

Market Cap Rank

#31264 Global

#1056 in UK

Share Price

GBX10.50

Change (1 day)

+0.00%

52-Week Range

GBX9.75 - GBX19.25

All Time High

GBX213.00